Sun Pharma Advanced Research Co Quarterly Results
Sun Pharma Advanced Research Co quarterly results. In Mar 2026, Sun Pharma Advanced Research Co (SPARC) reported revenue ₹15 Cr and net profit ₹1,761 Cr — revenue -44.4% YoY. Review SPARC P/E ratio to evaluate earnings-based valuation against sector peers.
SPARC Quarterly Results — Revenue, Profit & EPS Highlights
Sun Pharma Advanced Research Co latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Check SPARC market value to track the company's total market size over time.
- Revenue of ₹15 Cr in Mar 2026 (-76.6% vs Jun 2026, -44.4% vs Mar 2025)
- Net Profit of ₹1,761 Cr in Mar 2026 (+8485.7% vs Jun 2026, +3035.0% vs Mar 2025)
- EBITDA of ₹-65 Cr in Mar 2026 (-550.0% vs Jun 2026)
- Operating Margin of -506.0% in Mar 2026 (-421.0pp vs Jun 2026)
- Earnings Per Share of ₹54.27 in Mar 2026 (+8579.7% vs Jun 2026)
Sun Pharma Advanced Research Co Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SPARC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 15 | 64 | 8 | 27 | 19 | -76.6% | -44.4% |
| Net Profit (₹ Cr) | 1,761 | -21 | -76 | -60 | -52 | - | - |
| EBITDA (₹ Cr) | -65 | -10 | -66 | -53 | -43 | - | - |
| EPS (₹) | 54.27 | -0.64 | -2.34 | -1.84 | -1.60 | - | - |
| Operating Margin (%) | -506.0% | -85.0% | -836.0% | -196.0% | -540.0% | - | - |
SPARC Share Price Trend — 1-Year Movement Across Quarterly Results
Sun Pharma Advanced Research Co 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit SPARC screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SPARC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sun Pharma Advanced Research Co latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Cipla
Mar 2026 |
₹108,576.18 Cr | 1335.5 | 6,612 | 543 | -9.3% | - | 8.2% | 194.4 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores